That’s a fair point WAG but I’m more interested in Taysha’s share price getting smacked down ~25% on questionable trial results and NEU’s share price getting smacked down a similar percentage on fantastic trial results in PHS. Apples and oranges I know but it’s a funny old market….
While I’m here, the FDA has a new program called Operation Warp Speed for rare disease development I might write to Jon about it.
https://www.fiercebiotech.com/research/fda-selects-denali-neurogene-larimar-and-grace-sciences-rare-disease-therapy-pilot
Competitors to Daybue, page-18
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.87 |
Change
-0.300(1.49%) |
Mkt cap ! $2.576B | |||
| Open | High | Low | Value | Volume |
| $20.45 | $20.45 | $19.87 | $1.065M | 53.13K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 306 | $19.86 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.88 | 143 | 7 |
View Market Depth
| Last trade - 12.41pm 29/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |